{"prompt": "['MC1575', '46', 'Amendment 2', '13.0', 'TREATMENT/FOLLOW-UP DECISION AT EVALUATION OF PATIENT', '13.1', 'Continuation of treatment', 'Patients who are CR, PR, or SD will continue treatment per protocol.', '13.2', 'Progressive disease (PD)', 'Patients who develop PD while receiving therapy will go to the event-monitoring phase.', '13.3', 'Off protocol treatment', 'Patients who go off protocol treatment for reasons other than PD will go to the event-', 'monitoring phase per Section 4.', '13.4', 'Complete response', 'If the patient has achieved CR then treatment will continue for a maximum of 5 years', 'from time of registration.', '13.5', 'Duration of therapy for PR or SD', 'Patients who are in PR or SD will continue on therapy until PD or for maximum 5 years', 'from registration date and then they will go to event monitoring. Subsequent treatment is', 'at the discretion of their attending physician', '13.6', 'Progressive Disease (PD)', 'Patients who develop PD at any time should go to event monitoring.', '13.7', 'Inevaluable patients', 'If a patient fails to complete the first cycle of treatment for reasons other than toxicity,', 'the patient will be regarded as inevaluable and will be replaced.', '13.8', 'Ineligible', 'A patient is deemed ineligible if after registration, it is determined that at the time of', 'registration, the patient did not satisfy each and every eligibility criteria for study entry.', 'The patient may continue treatment off-protocol at the discretion of the physician as long', 'as there are no safety concerns, and the patient was properly registered. The patient will', 'go directly to the event-monitoring phase of the study (or off study, if applicable).', 'If the patient received treatment, all data up until the point of confirmation of', 'ineligibility must be submitted. Event monitoring will be required per Section 18.0 of', 'the protocol.', 'If the patient never received treatment, on-study material must be submitted. Event', 'monitoring will be required per Section 18.0 of the protocol.', '13.9a', 'Major violation', 'A patient is deemed a major violation, if protocol requirements regarding treatment in', 'cycle 1 of the initial therapy are severely violated that evaluability for primary end point', 'is questionable. All data up until the point of confirmation of a major violation must be', 'submitted. The patient will go directly to the event-monitoring phase of the study. The', 'patient may continue treatment off-protocol at the discretion of the physician as long as', 'there are no safety concerns, and the patient was properly registered. Event monitoring', 'will be required per Section 18.0 of the protocol.', 'Protocol Version Date:16Aug2018']['MC1575', '47', 'Amendment 2', '13.9b Cancel', 'A patient is deemed a cancel if he/she is removed from the study for any reason before', 'any study treatment is given. On-study material and the End of Active Treatment/Cancel', 'Notification Form must be submitted. No further data submission is necessary.', '14.0', 'BODY FLUID BIOSPECIMENS', 'Optional blood and urine specimen for correlative studies will be collected from Mayo Clinic', 'patients at baseline for Mayo Clinic biomarker study (IRB 13-005838) . Patient will be consented', 'separately for the study and provided with study card for blood and urine collection. Collection,', 'transport and processing should follow IRB 13-005838 instructions.', 'Protocol Version Date:16Aug2018']['MC1575', '48', 'Amendment 2', '15.0', 'DRUG INFORMATION', '15.1', 'Lenvatinib (E7080, LenvimaR)', '15.11', 'Background: Lenvatinib is an oral, multiple receptor tyrosine kinase (RTK)', 'inhibitor that selectively inhibits the kinase activities of vascular endothelial', 'growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and', 'VEGFR3 (FLT4), in addition to other proangiogenic and oncogenic pathway-', 'related RTKs including fibroblast growth factor (FGF) receptors FGFR1, 2, 3,', 'and 4; the platelet derived growth factor (PDGF) receptor PDGFRa; KIT; and', 'RET.', '15.12', 'Formulation: Lenvatinib is available as 4 mg and 10 mg capsules. The following', 'are capsule inactive ingredients: Calcium Carbonate, USP; Mannitol, USP;', 'Microcrystalline Cellulose, NF; Hydroxypropyl Cellulose, NF; Hydroxypropyl', 'Cellulose (type H), NF; and Talc, USP. The hypromellose capsule shell contains', 'titanium dioxide, ferric oxide yellow, and ferric oxide red. The printing ink', 'contains shellac, black iron oxide, potassium hydroxide, and propylene glycol.', '15.13', 'Preparation and storage: Store at controlled room temperature, 25 degrees C', '(77 degrees F), with excursions permitted between 15 and 30 degrees C (59 and', '86 degrees F)', '15.14 Administration: Take lenvatinib at the same time each day with or without food.', 'The capsules should be swallowed whole with water. Alternatively, add the', 'lenvatinib capsules to a tablespoon of water or apple juice in a small glass to', 'produce a suspension. Leave the capsules in the liquid for at least 10 minutes.', 'Stir for at least 3 minutes. Drink the mixture. After drinking, add the same', 'amount of water or apple juice (one tablespoon) to the glass. Swirl the contents', 'of the glass a few times and swallow the additional liquid. If a patient misses a', 'dose, and it cannot be taken within 12 hours, then that dose should be skipped', 'and the next dose should be taken at the usual time of administration.', '15.15', 'Pharmacokinetic information:', 'Absorption: Lenvatinib is rapidly absorbed after oral administration with tmax', 'typically observed from 1 to 4 hours postdose. Food does not affect the extent of', 'absorption, but slows the rate of absorption. When administered to healthy', 'subjects with food, peak plasma concentrations are delayed by 2 hours.', 'Distribution: In vitro binding of lenvatinib to human plasma proteins is high', 'and ranged from 98% to 99% (0.3 - 30 g/mL, mesilate). This binding was', 'mainly to albumin with minor binding to al-acid glycoprotein and Y-globulin. In', 'vitro blood to plasma ratios of lenvatinib (0.1 - 10 g/mL) remained constant in', 'humans (0.589 - 0.608).', 'Metabolism: Lenvatinib is extensively metabolized in humans. The main', 'metabolic pathways in humans were identified as oxidation by AO,', 'demethylation via CYP3A4, glutathione conjugation with elimination of the O-', 'aryl group (chlorbenzyl moiety), and combinations of these pathways followed', 'by further biotransformations (eg, glucuronidation, hydrolysis of the glutathione', 'moiety, degradation of the cysteine moiety, and intramolecular rearrangement of', 'the cysteinylglycine and cysteine conjugates with subsequent dimerization).', 'Half-life elimination: Plasma concentrations decline bi-exponentially following', 'Cmax. The terminal exponential half-life of lenvatinib is about 28 hours.', 'Protocol Version Date:16Aug2018']\n\n###\n\n", "completion": "END"}